Tangri N, Ferguson T, Leon SJ, Anker SD, Filippatos G, Pitt B, et al
Therapeutic inertia in intensification of insulin therapy should be avoided and, when clinicians are not familiar with multiple daily injection therapy, referral to specialist care and/or DSMES is warranted
Engaging in informed discussion with your healthcare provider is essential for determining whether GLP-1 therapy is appropriate for you and, if so, which specific agent best aligns with your clinical needs and personal preferences
Pen-sharing poses a risk for transmission of blood-borne pathogens Hypoglycemia: Patients receiving Ozempic in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia
By optimizing 3 FUNCTIONS , GLP-1s ensure that you have more than just a temporary solution
If symptoms do not resolve, additional evaluation should be considered